ArticleProstate cancer and prostatic diseases2020

Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC).

Charles J Ryan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.